Investigating how HBV RNaseH inhibitors affect hepatitis B virus biology and resistance
HBV RNaseH inhibitors: Effects on HBV biology and resistance development
This study is looking at a specific enzyme that helps the hepatitis B virus multiply, and it's trying to find new medicines that can stop this enzyme from working, which could help people with chronic hepatitis B feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10741786 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of the ribonuclease H (RNaseH) enzyme in the replication of the hepatitis B virus (HBV). By developing a screening pipeline for RNaseH inhibitors, the study aims to identify compounds that can effectively block HBV replication. Patients may benefit from new therapeutic options that target this enzyme, potentially leading to improved outcomes for those with chronic HBV infections. The research employs advanced techniques in cell culture and drug discovery to explore these inhibitors.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic hepatitis B virus infections who have not responded adequately to existing therapies.
Not a fit: Patients who are not infected with hepatitis B virus or those who have already cleared the virus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help clear hepatitis B virus from patients, reducing the need for lifelong therapy.
How similar studies have performed: Other research has shown promise in targeting viral enzymes for therapeutic development, indicating that this approach could yield significant advancements in hepatitis B treatment.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Tavis, John E — Saint Louis University
- Study coordinator: Tavis, John E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.